FRANKFURT, Germany (AP) – German drug company Merck says it has agreed to buy St Louis-based chemical firm Sigma-Aldrich Corp for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment.
Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich’s shares – a premium of 37 per cent over Friday’s closing price of $102.37.
Sigma-Aldrich has over 9,000 employees worldwide and supplies chemicals and laboratory equipment to government and commercial facilities. It said its board of directors has unanimously approved the deal, which is expected to close next year, subject to regulators’ approval.
Sigma-Aldrich CEO Rakesh Sachdev said the deal was a “very positive outcome” for shareholders due to the price premium and for employees, “who will benefit from enhanced opportunities as part of a larger, more global organisation.”
Merck said it would expand the reach of its EMD Millipore chemical and equipment division, based in Billerica, Massachusetts. “In one of the world’s key industries two companies that fit perfectly together have found each other to present a much broader product offering to our global customers” in research facilities and drug manufacturing, said Merck CEO Karl-Ludwig Kley.
Employees of pharmaceutical company Merck Serono stage a die-in during a demonstration in front of the pharmaceutical company Merck, in Geneva, Switzerland, on June 19, 2012. Merck says it has agreed to buy St Louis-based chemical firm Sigma-Aldrich Corp for $17 billion in a deal Merck says will strengthen its business in chemicals and laboratory equipment – EPA
Merck said the combination would enable it to save 260 million euros ($340 million dollars) a year in costs within three years after closing the deal. The company said, however, that it would maintain a “significant presence” in both Billerica and St Louis.
Merck shares shot up on the announcement, trading 8.9 per cent higher at 75.82 euros.
The company said it already had financing for the deal and would pay using a combination of cash, bank loans and bonds.
Merck KGaA is not affiliated with US drug maker Merck & Co.